Hydroxymethylglutaryl-coenzyme A reductase inhibitors and osteoporosis: A meta-analysis

Osteoporosis International

Volumn 16, Issue 8, 2005, Pages 990-998

  Hatzigeorgiou, Christos ^a   Jackson, Jeffrey L ^b,c  

^a TRIPLER ARMY MEDICAL CENTER   (United States)

^b EDP   (United States)

^c UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

Bone marker; Bone mineral density; Fracture; HMG CoA reductase inhibitors; Meta analysis; Osteoporosis; Statin

Indexed keywords

ALKALINE PHOSPHATASE; ATORVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; OSTEOCALCIN; PRAVASTATIN; SIMVASTATIN;

ANALYTIC METHOD; ARTICLE; BONE DENSITY; BONE METABOLISM; CLINICAL TRIAL; COCHRANE LIBRARY; EMBASE; FRACTURE; HIP FRACTURE; HUMAN; MEDLINE; META ANALYSIS; OSTEOPOROSIS; OUTCOMES RESEARCH; PRIORITY JOURNAL; RISK ASSESSMENT; STATISTICAL SIGNIFICANCE; SYSTEMATIC REVIEW; VERTEBRA FRACTURE;

BONE DENSITY; EPIDEMIOLOGIC METHODS; FEMALE; FRACTURES, BONE; HIP FRACTURES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; OSTEOPOROSIS;

EID: 23744495979     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-004-1793-0     Document Type: Article

References (55)

1. Ansell BJ, Watson KE, Weiss RE, Fonarow GC (2003) CRP and HDL effects of statins trial (CHEST): rapid effect of statin therapy on C-reactive protein and high-density lipoprotein levels. A clinical investigation. Heart Dis 5:2-7)
2. Horne BD, Muhlestein JB, Carlquist JF, Bair TL, Madsen TE, Hart NI, Anderson JL (2003) Statin therapy interacts with cytomegalovirus seropositivity and high C-reactive protein in reducing mortality among patients with angiographically significant coronary disease. Circulation 107:258-263
3. Plenge JK, Hernandez TL, Weil KM, Poirier P, Grunwald GK, Marcovina SM, Eckel RH (2002) Simvastatin lowers C-reactive protein within 14 days: an effect independent of low-density lipoprotein cholesterol reduction. Circulation 106:1447-1452
4. Koh KK, Son JW, Ahn JY, Jin DK, Kim HS, Choi YM, Kim DS, Jeong EM, Park GS, Choi IS, Shin EK (2002) Comparative effects of diet and statin on NO bioactivity and matrix metalloproteinases in hypercholesterolemic patients with coronary artery disease. Arterioscler Thromb Vasc Biol 22:e19-23
5. Bickel C, Rupprecht HJ, Blankenberg S, Espiniola-Klein C, Schlitt A, Rippin G, Hafner G, Treude R, Othman H, Hofmann KP, Meyer J (2002) Relation of markers of inflammation (C-reactive protein, fibrinogen, von Willebrand factor, and leukocyte count) and statin therapy to long-term mortality in patients with angiographically proven coronary artery disease. Am J Cardiol 89:901-908
6. Mundy G, Garret R, Harris S, Chan J, Chen D, Rossini G, Boyce B, Zhao M, Gutierrez G (1999) Stimulation of bone formation in vitro and in rodents by statins. Science 286:1946-1949
7. Bauer DC (2003) HMG CoA reductase inhibitors and the skeleton: a comprehensive review. Osteoporos Int 14:273-282
8. Luckman SP, Hughes DE, Coxon FP (1998) Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational phenylation of GTP-binding proteins, including ras. J Bone Miner Res 13:581-589
9. Woo J, Kasai S, Stern P, Nagai K (2000) Compactin suppresses bone resorption by inhibiting the fusion of prefusion osteoclasts and disrupting the actin ring in osteoclasts. J Bone Miner Res 15:650-658
10. Harris RP, Helfand M, Woolf SH, et al (2001) Current methods of the US preventive services task force. A review of the process. Am J Prev Med 20:21-35
11. Follman D, Elliott P, Suh I, Cutler J (1992) Variance imputation for overviews of clinical trials with continuous response. J Clin Epidemiol 45:769-773
12. Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50:1088-1101
13. Duval S, Tweedie R (2000) Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 56:455-463
14. Galbraith RF (1988) A note on graphical presentation of estimated odds ratios from several clinical trials. Stat Med 7:889-894
15. Mantel N, Haenszel W Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 29:719-748
16. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials. 7:177-188
17. Thompson SG, Sharp SJ (1999) Explaining heterogeneity in meta-analysis: a comparison of methods. Stat Med 18:2693-2708
18. Chung YS, Lee MD, Lee SK, Kim HM, Fitzpatrick LA (2000) HMG-CoA reductase inhibitors increase BMD in type 2 diabetes mellitus patients. J Clin Endocrinol Metab 85:1137-1142
19. Edwards CJ, Hart DJ, Spector TD (2000) Oral statins and increased bone-mineral density in postmenopausal women. Lancet 355:2218-2219
20. Van Staa TP, Wegman S, de Vries F, Leufkens B, Cooper C (2001) Use of statins and risk of fractures. JAMA 285:1850-1855
21. Wang PS, Solomon DH, Mogun H, Avorn J (2000) HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients. JAMA 283:3211-3216
22. Meier CR, Schlienger RG, Kraenzlin ME, Schlegel B, Jick H (2000) HMG-CoA reductase inhibitors and the risk of fractures. JAMA 283:3205-3210
23. Rejnmark L, Olson ML, Johnsen SP, Vestorgaar P, Sorenson HT, Mosekilde L (2004) Hip fracture risk in statin users: a population based, Danish case-control study. Osteoporos Int 15:452-458
24. Chan KA, Andrade SE, Boles M, et al (2000) Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women. Lancet 355:2185-2188
25. Barengolts E, Karanouh D, Kolodny L, Kukreja S (2001) Risk factors for hip fractures in predominantly African-American veteran male population. J Bone Miner Res 16 [Suppl 1]:S170
26. Sirola J, Honkanen R, Kroger H, et al (2002) Relation of statin use and bone loss: a prospective population-based cohort study in early postmenopausal women. Osteoporos Int 13:537-541
27. Cauley JA, Jackson R, Pettinger M, et al (2000) Statin use and bone mineral density in older women: the women's health initiative observational study (WHI-OS). J Bone Miner Res 15 [Suppl]:1068
28. Bauer DC, Mundy GR, Jamal SA, et al (1999) Statin use, bone mass and fracture: an analysis of two prospective studies. J Bone Miner Res 14 [Suppl]:1188
29. LaCroix AZ, Cauley JA, Jackson R, et al (2000) Does statin use reduce risk of fracture in postmenopausal women? Results from the women's health initiative observational study. J Bone Miner Res 15 [Suppl]:1066
30. Mostaza JM, Concepcion De la Piedra, et al (2001) Pravastatin therapy increases procollagen I n-terminal propeptide (pinp), a marker of bone formation in post-menopausal women. Clin Chim Acta 308:133-137
31. Bauer DC, Mundy GR, Jamal SA, Black DM, Cauley JA, Ensrud K, van der Dlift M, Pols HAP (2004) Results of 4 prospective studies and cumulative meta-analysis of observational studies and controlled trials. Arch Intern Med 164:146-152
32. Montagnani A, Gonnelli S, Cepollaro C, Pacini S, Campagna MS, Franci MB, Lucani B, Gennari C (2003) Effect of simvastatin treatment on bone mineral density and bone turnover in hypercholesterolemic postmenopausal women: a 1-year longitudinal study. Bone 23:427-433
33. LaCroix AZ, Cauley JA, Pettinger M, Hsia J, Bauer DC, McGowan J, Chen Z, Lewis CE, McNeeley G, Passaro MD, Jackson RD (2003) Statin use, clinical fracture and bone density in postmenopausal women: results from the Women's Health Initiative Observational Study. Ann Intern Med 139:97-104
34. Lupattelli G, Scarpon AM, Donatella GV, Siepi D, Roscini AR, Gemelli F, Pirro M, Latini RA, Sinzinger H, Marchesi S, Mannarino E (2004) Metabolism. 53:744-748
35. Wada Y, Nakamura Y, Koshiyama H (2000) Lack of positive correlation between statin use and bone mineral density in Japanese subjects with type 2 diabetes. Arch Intern Med 160:2865
36. Funkhouser HL, Tilahun A, Adler RA (2002) Effect of HMG-CoA reductase inhibitors (statins) on bone mineral density. J Clin Densitom 5:152-158
37. Pasco JA, Kotowicz MA, Henry MH, et al (2002) Statin use, bone mineral density, and fracture. Arch Intern Med 162:537-540
38. Rejnmark L, Buus NH, Vestergaard P, et al (2002) Statins decrease bone turnover in postmenopausal women: a cross sectional study. Eur J Clin Invest 32:581-589
39. Ray WA, Daugherty JR, Griffin MR (2002) Lipid lowering agents and the risk of hip fracture in a Medicaid population. Inj Prev 8:276-279
40. Watanabe S, Fukumoto S, Takeuchi Y, et al (2001) Effects of 1-year treatment with fluvastatin or pravastatin on bone. Am J Med 110:584-587
41. Reid IR, Hague W, Emberson J, et al (2001) Effect of pravastatin on frequency of fracture in the LIPID study: secondary analysis of a randomized controlled trial. Lancet 357:509-512
42. Pederson TR, Kjekshus J (2000) Statin drugs and the risk of fracture. JAMA 284:1921-1922
43. Bjarnason NH, Riis BJ, Christiansen C (2001) The effect of fluvastatin on bone remodeling. Osteoporos Int 12:380-384
44. Hsia J, Morse M, Levin V (2002) Effect of simvastatin on bone markers in osteopenic women: a placebo-controlled, dose-ranging trial. BMC Musculoskelet Disord 3:1-5
45. Stein EA, Farnier M, Waldstreicher J, Mercuri M (2001) Effects of statins on biomarkers of bone metabolism: a randomised trial. Nutr Metab Cardiovasc Dis 11:84-87
46. Rejnmark L, Buus NH, Vestergaard P, Heickendorrf L, Andreasen F, Larsen ML, Mosekilde L (2004) Effects of simvastatin on bone turnover and BMD: a 1-year randomized controlled trial in postmenopausal osteopenic women. J Bone Miner Res 19:737-744
47. Looker AC, Bauer DC, Chestnut CH, et al (2000) Clinical use of biochemical bone markers of bone remodeling: current status and future direction. Osteoporos Int 11:467-480
48. Brown JP, Josse RG (2002) Clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ 167 [10 Suppl]:s1-s27
49. Hamelin BA, Turgeon J (1998) Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors. Trends Pharmacol Sci 19:26-37
50. Sugiyama M, Kodama T, et al (2000) Compactin and simvastatin, but not pravastatin, induce bone-morphogenetic protein-2 in human osteosarcoma cells. Biochem Biophys Res Commun 271:699-692
51. Hennessy S, Strom BL (2001) Statins and fracture risk. JAMA 285:1888-1889
52. Marshall D, Johnell O (1996) Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 312:1254-1259
53. Osteoporosis among estrogen-deficient women - United States, 1988-1994. MMWR Morb Mortal Wkly Rep 47:969-973
54. Fisher ES, Baron JA, Malenka DJ, et al (1991) Hip fracture incidence and mortality in New England. Epidemiology 2:116-122
55. Marottoli RA, Berkman LF, Cooney LM (1992) Decline in physical function following hip fracture. J Am Geriatr Soc 40:861-866